Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clayton et al. reported the expression of CD39, CD73, and eADO in MPM-derived exosome from pleural effusion, contributing to the inhibition of T cell functions [133].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 1×
“To quantify the density of exosomes, we used a protocol similar to that previously described, based on ultracentrifugation on a linear sucrose gradient (36).”
MethodSelf-citationMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882 · cited 1×
“immune-activating functions, there are also accumulating data pointing to varied suppressive effects (40).”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The density (g/ml) of each fraction was calculated from the published table in the Beckman Ultracentrifugation catalogue as described (37).”
MethodDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 5×
“These are double-positive for CD39 and CD73 in mice (12) and according to one report also in human (45).”
BackgroundInfluentialOhta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286 · cited 3×
“Natural regulatory T cells of mice express both CD39 and CD73, whose coordinated enzymatic actions produce adenosine as a mechanism for immune suppression that is independent of IL-10 and TGF-b (12, 13).”
BackgroundAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“mechanisms involved in adenosine formation and subsequent signaling are therefore of considerable therapeutic interest (9).”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“Adenosine also represses immune responses in the tumor microenvironment, assisting tumor immune evasion (7, 8).”
BackgroundMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953 · cited 7×
“The cushion was collected and exosomes washed in PBS (32, 34, 35).”
MethodInfluentialExoCarta: A compendium of exosomal proteins and RNA
Mathivanan, S., & Simpson, R. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900351 · Cited by 873
Cited by
Items 301–400 of 564
Krivitsky, V., Krivitsky, A., Mantella, V., Greenwald, M. B., Sankar, D. S., Betschmann, J., Bader, J., Zoratto, N., Schreier, K., Feiss, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202212000 · Cited by 31
Composition, functions, and applications of exosomal membrane proteins
Xu, F., Luo, S., Lu, P., Cai, C., Li, W., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408415 · Cited by 33
Wu, X., Meng, Y., Yao, Z., Lin, X., Hu, M., Cai, S., Gao, S., & Zhang, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107751 · Cited by 29
Considerations for Applying Metabolomics to the Analysis of Extracellular Vesicles
Palomo, L., Casal, E., Royo, F., Cabrera, D., Liempd, S. M. V., & Falcón‐Pérez, J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00651 · Cited by 28
“Clayton and collaborators have showed that EVs modify the extracellular adenosine levels, which has important implications for the activation of the immune system (29).”
BackgroundCD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives
Soleimani, A., Taghizadeh, E., Shahsavari, S., Amini, Y., Rashidpour, H., Azadian, E., Jafari, A., Parizadeh, M. R., Mashayekhi, K., Soukhtanloo, M., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28187 · Cited by 29
Ruf, J., Vairo, D., Paganelli, F. F., & Guieu, R. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14564 · Cited by 28
“25 In CAD, one could hypothesize that A 2A R circulate from donor cells to target cells as a salvage pathway to be stimulated by adenosine when vasodilation is required for oxygen delivery in failing artery tissues.”
BackgroundExosomes: Emerging Players of Intercellular Communication in Tumor Microenvironment
Maheshwari, S., Singh, A. K., Arya, R. K., Pandey, D., Singh, A., & Datta, D. B. (2014) · Discoveries · doi:10.15190/d.2014.18 · Cited by 28
Exosomes Exercise Inhibition of Anti-Tumor Immunity during Chemotherapy
LeBleu, V. S., & Kalluri, R. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.019 · Cited by 28
Role of exosome-associated adenosine in promoting angiogenesis
Ludwig, N., Jackson, E. K., & Whiteside, T. L. (2020) · Vessel Plus · doi:10.20517/2574-1209.2019.37 · Cited by 27
“Exosomes from diverse cancer cell types exhibit potent ATPand 5’-AMP-phosphohydrolytic activity, partly attributed to activity of CD39 and CD73, respectively, on the surface of exosomes[19].”
BackgroundSenescent Tumor CD8+ T Cells: Mechanisms of Induction and Challenges to Immunotherapy
Liu, W., Stachura, P., Xu, H. C., Bhatia, S., Borkhardt, A., Lang, P. A., & Pandyra, A. A. (2020) · Cancers · doi:10.3390/cancers12102828 · Cited by 27
“For instance adenosine, whose production is catalyzed by the surface ectonucleotidases CD39 and CD73, accumulates in the TME through CD38 and CD73 expression on cancer exosomes [51].”
BackgroundThe crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer
Iser, I. C., Vedovatto, S., Oliveira, F. D., Beckenkamp, L. R., Lenz, G., & Wink, M. R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.012 · Cited by 31
Bano, A., Vats, R., Yadav, P., & Bhardwaj, R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103799 · Cited by 27
Cellular Migration Ability Is Modulated by Extracellular Purines in Ovarian Carcinoma SKOV‐3 Cells
Martínez-Ramírez, A. S., Díaz‐Muñoz, M., Battastini, A. M. O., Campos‐Contreras, A. D. R., Olvera, A., Bergamin, L. S., Glaser, T., Moritz, C. E. J., Ulrich, H., & Vázquez‐Cuevas, F. G. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26104 · Cited by 28
“the eventual fusion of these exosomes confers target cells the molecular machinery for adenosine synthesis [Clayton et al., 2011].”
BackgroundThe Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia
D’Antongiovanni, V., Fornai, M., Pellegrini, C., Benvenuti, L., Blandizzi, C., & Antonioli, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145089 · Cited by 29
Dillard, C., Borde, C., Mohammad, A., Puchois, V., Jourdren, L., Larsen, A. K., Sabbah, M., Maréchal, V., Escargueil, A. E., & Pramil, É. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111472 · Cited by 29
Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy
Rasihashemi, S. Z., Rezazadeh‐Gavgani, E., Majidazar, R., Seraji, P., Oladghaffari, M., Kazemi, T., & Lotfinejad, P. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30645 · Cited by 26
“This action contributes to the attenuation of T‐cell response (Clayton et al., 2011).”
BackgroundModulation of Cellular Function Through Immune-Activated Exosomes
Pulliam, L., & Gupta, A. A. (2015) · DNA and Cell Biology · doi:10.1089/dna.2015.2884 · Cited by 27
“Alternatively, engagement of the surface receptors on the exosomes with membrane proteins of the recipient cell may trigger a downstream signaling cascade that can impact cell function (Clayton et al., 2011).”
BackgroundBiodistribution, Uptake and Effects Caused by Cancer-Derived Extracellular Vesicles
Sadovska, L., Bajo-Santos, C., Kalniņa, Z., & Linē, A. (2015) · Journal of Circulating Biomarkers · doi:10.5772/60522 · Cited by 26
“Other EV-mediated immunosuppressive mechanisms include T cell inhibition via the production of extracellular adenosine by EV-expressed CD39 and CD73 [106], and the downregulation of the activating receptor NKG2D on NK and CD8+ T cells by EV-transferred TGFβ [103, 107].”
BackgroundGennaro, P. D., Gerlini, G., Caporale, R., Sestini, S., Brandani, P., Urso, C., Pimpinelli, N., & Borgognoni, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.032 · Cited by 26
Lucien, F., Kim, Y., Qian, J., Orme, J. J., Zhang, H., Arafa, A., Abraha, F., Thapa, I., Tryggestad, E. J., Harmsen, W. S., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.037 · Cited by 25
Exosomal miRNAs and breast cancer: a complex theranostics interlink with clinical significance
Mukherjee, S., Dhar, R., Jonnalagadda, S., Gorai, S., Nag, S., Kar, R., Mukerjee, N., Mukherjee, D., Vatsa, R., Devi, A., et al. (2023) · Biomarkers · doi:10.1080/1354750x.2023.2229537 · Cited by 26
“…hydrolytic activity, produces adenosine from AtP. these adenosine levels around micromolar concentrations have immunosuppressive functions on t cells (Blay et al. 1997, Mandapathil et al. 2010), finally contributing to host immune system dysregulation to promote cancer growth (clayton et al. 2011).”
BackgroundPurinergic enzymes on extracellular vesicles: immune modulation on the go
Winzer, R., Nguyen, D. H., Schoppmeier, F., Cortesi, F., Gagliani, N., & Tolosa, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362996 · Cited by 26
Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma
Jin, K., Mao, C., Chen, L., Wang, L., Liu, Y., & Yuan, J. (2021) · Cancers · doi:10.3390/cancers13020229 · Cited by 27
EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC
Słomka, A., Mocan, T., Wang, B., Nenu, I., Urban, S., Gonzalez-Carmona, M. A., Schmidt‐Wolf, I. G. H., Kornek, M., Strassburg, C., Sparchez, Z. A., et al. (2020) · Cancers · doi:10.3390/cancers12103019 · Cited by 26
“CD39 and CD73, both present on some tumour-derived EVs, are involved in inhibiting the immune response in the inflammatory tumour environment, promoting tumour immune escape and affecting the chemotherapeutic effect to a great extent [129,130].”
BackgroundZhang, X., Greve, P. F., Minh, T. T. N., Wubbolts, R., Demir, A. Y., Zaal, E. A., Berkers, C. R., Boes, M. L., & Stoorvogel, W. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12457 · Cited by 24
Schuler, P. J., Westerkamp, A. M., Kansy, B., Bruderek, K., Dissmann, P. A., Dumitru, C. A., Lang, S., Jackson, E. K., & Brandau, S. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.01.013 · Cited by 24
Texidó, L., Romero, C., Vidal, A., García‐Valero, J., Fernández-Montolí, M.-E., Baixeras, N., Condom, E., Ponce, J., García‐Tejedor, A., & Martín-Satué, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/120673 · Cited by 24
“Membranes were then incubated overnight at 4∘C with the following antibodies: exosomal marker antibodies CD9, CD63, CD81, HSP70 (diluted 1 : 1000) from the ExoAB-KIT1 Western blot antibody detection kit (System Biosciences), anti-CD39 (clone BU61, diluted 1 : 500), and anti-CD73 (clone 4G4 fromAbcam, diluted 1 : 50).”
ResultInfluentialDysfunctional purinergic signaling correlates with disease severity in COVID-19 patients
Pietrobon, A. J., Andrejew, R., Custódio, R. W. A., Oliveira, L. D. M., Scholl, J. N., Teixeira, F. M. E., de Brito, C. A., Glaser, T., Kazmierski, J., Goffinet, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012027 · Cited by 23
The role of exosomes in colorectal cancer disease progression and response to therapy
Bracci, L., Lozupone, F., & Parolini, I. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.004 · Cited by 25
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell
Yeo, R. W. Y., Lai, R. C., Tan, K. H., & Lim, S. K. (2013) · Journal of Circulating Biomarkers · doi:10.33393/jcb.2013.2038 · Cited by 25
High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma
Xu, Y., Zhou, Y., Zhao, Y., Zhao, Y. F., Wang, F., Huang, X., & Guo, C.-Y. (2021) · Journal of Cancer · doi:10.7150/jca.51038 · Cited by 22
“an ectonucleotidase that cooperates in the extracellular adenosine production through ATP hydrolysis to attack the balance of immunosuppressive microenvironments, indicating that CD73 could depress the CD8+T cell responses [17-20].”
BackgroundYi, Y. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043704 · Cited by 23
“TEVs also play immunosuppressive roles by attenuating the function of natural killer cells [49,59] and T cells [46], and by enhancing the differentiation of myeloid-derived suppressor cells [52].”
BackgroundSurface Desorption Dielectric-Barrier Discharge Ionization Mass Spectrometry
Zhang, H., Jiang, J., Li, N., Li, M., Wang, Y., He, J. F., & You, H. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b00323 · Cited by 22
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Kotulová, J., Hajdúch, M., & Džubák, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212569 · Cited by 23
“Exosomes released from tumour cells express CD39 and CD73, which increase ADO levels in the TME and suppress T cells’ functions [140].”
BackgroundOpportunities and Challenges for anti-CD73 Cancer Therapy
Zhang, B. (2012) · Immunotherapy · doi:10.2217/imt.12.83 · Cited by 21
The Role of Tumor-Derived Exosomes (TEX) in Shaping Anti-Tumor Immune Competence
Whiteside, T. L. (2021) · Cells · doi:10.3390/cells10113054 · Cited by 21
“ADO produced by TEX was shown to inhibit T-cell activation and proliferation through A2ARs [28].”
BackgroundYang, X., Zhou, Y., Zhou, F., Bao, L., Wang, Z., Li, Z., Ding, F., Kuang, H., Liu, H., Tan, S., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s491222 · Cited by 20
“42 As to T cell-derived EVs, the enrichment of CD73 on EVs derived from CD8 T cells hydrolyzes AMP and promotes the production of adenosine, which plays an immunosuppressive role.”
Horigome, E., Fujieda, M., Handa, T., Katayama, A., Ito, M., Ichihara, A., Tanaka, D., Gombodorj, N., Yoshiyama, S., Yamane, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26177 · Cited by 20
Mezzasoma, L., Bellezza, I., Orvietani, P., Manni, G., Gargaro, M., Sagini, K., Llorente, A., Scarpelli, P., Pascucci, L., Cellini, B., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101657r · Cited by 20
Tumor-derived vesicles in immune modulation: focus on signaling pathways
Yin, F., He, Y., Qiao, Y., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1581964 · Cited by 25
“Clayton et al. (81) also showed the impact of adenosine generation on T cell function and demonstrated that the production of in fl ammatory cytokines and the proliferative responses of T cells could be effectively suppressed by AMP as a substrate.”
InfluentialCancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints
Yin, X., Yang, Y., & Liu, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-04001-0 · Cited by 19
“The expression of CD39 and CD73 on myeloid-derived suppressor cells (MDSCs) inside the tumor micro-environment is subject to regulation by transforming growth factor beta (TGF-β) and hypoxia-inducible factor 1-alpha (HIF-1) [41, 42].”
Basak, M., Chaudhary, D. K., Takahashi, R., Yamamoto, Y., Tiwari, S., Tahara, H., & Mittal, A. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00893 · Cited by 20
Shi, M., Ye, L., Zhao, L., He, L., Chen, J., Zhang, J., Su, Y., Dong, H., Liu, J., Liang, L., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01654-2 · Cited by 19
“Accumulating evidence shows that tumor-associated proteins anchored on the tumor cell membrane can be released into the TME, where they can induce a series of downstream cascades involving the release of exosomes that alter the function of immunocytes [8].”
BackgroundAdenosine receptors regulate exosome production
Ludwig, N., Azambuja, J. H., Rao, A., Gillespie, D. G., Jackson, E. K., & Whiteside, T. L. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09700-7 · Cited by 20
Adenosine Receptor A2B Negatively Regulates Cell Migration in Ovarian Carcinoma Cells
Campos‐Contreras, A. D. R., González‐Gallardo, A., Díaz‐Muñoz, M., & Vázquez‐Cuevas, F. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094585 · Cited by 19
“Since cancer cells secretes exosomes expressing CD39 and CD73, enzymes necessary to convert ATP in ADO [35,36], is plausible to hypothesize that ADO acting through A2BR could be contributors to secondary tumor formation.”
BackgroundImmunometabolism of human autoimmune diseases: from metabolites to extracellular vesicles
de Candia, P., Rosa, V. D., Gigantino, V., Botti, G., Ceriello, A., & Matarese, G. (2017) · FEBS Letters · doi:10.1002/1873-3468.12733 · Cited by 27
“It is interesting to point out here that a very similar strategy of immune suppression is also employed by cancer cells through the release of EVs able to modify the extracellular adenosine level [116].”
Yun, S. J., Lee, B., Komori, K., Lee, M. J., Lee, B. G., Kim, K. H., & Park, S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.12.006 · Cited by 20
Tutanov, O. S., Glass, S. E., & Coffey, R. J. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.17 · Cited by 18
Fyfe, J., Dye, D. E., Razak, N. B. A., Metharom, P., & Falasca, M. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.004 · Cited by 19
The first CD73-instructed supramolecular hydrogel
Wu, D., Du, X., Shi, J., Zhou, J., Zhou, N., & Xu, B. (2014) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.11.050 · Cited by 18
Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells
Clayton, S. M., Archard, J. A., Wagner, J., Farwell, D. G., Bewley, A. F., Beliveau, A. M., Birkeland, A. C., Rao, S. S. D., Abouyared, M., Belafsky, P. C., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0197 · Cited by 19
“CD39 hydrolyzes ATP into 5¢ AMP and CD73 hydrolyzes 5¢ AMP into adenosine [95,96].”
Texosome-based drug delivery system for cancer therapy: from past to present.
Hosseini, H. M., Halabian, R., Amin, M., & Fooladi, A. A. I. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0045 · Cited by 20
Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17
Self-citationCritical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers
Kara-Terki, L., Treps, L., Blanquart, C., & Fradin, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176024 · Cited by 17
“CD39, CD73 Pleural effusions Adenosine production T cell suppression MPM [38]”
BackgroundExtracellular vesicle-mediated communication between CD8+ cytotoxic T cells and tumor cells
Huang, Z., Liu, X., Guo, Q., Zhou, Y., Shi, L., Cai, Q., Tang, S., Ouyang, Q., & Zheng, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1376962 · Cited by 19
“Clayton et al. demonstrated that exosomes carry CD39 and CD73, resulting in the inhibition of CD8 + T cells by converting ATP into adenosine (76).”
BackgroundRubenich, D. S., Domagalski, J. L., Gentil, G. F. S., Eichberger, J., Fiedler, M., Weber, F., Federlin, M., Poeck, H., Reichert, T. E., Ettl, T., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12480 · Cited by 18
van Heusden, C. A., Button, B. M., Anderson, W. H., Ceppe, A., Morton, L. C., O’Neal, W. K., Dang, H., Alexis, N. E., Donaldson, S. H., Stephan, H., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00449.2019 · Cited by 17
“In this regard, Clayton and coworkers (7) demonstrated that plasma membrane-tethered ecto-nucleotidases associated with secreted exosomes accounted for 20% of the total ATP-hydrolytic activity in pleural effusions from patients with mesothelioma.”
BackgroundSoroczyńska, K., Zaręba, Ł., Długołęcka, M., & Czystowska, M. (2022) · Cells · doi:10.3390/cells11091483 · Cited by 20
“The functional ectonucleotidases CD39 and CD73 transferred by EVs, hydrolyse exogenous ATP and cAMP to adenosine [40].”
BackgroundBarros, E., Carotti, V., Vries, C. R. S., Witsel, F., Arntz, O. J., van de Loo, F. A. J., Carvajal, C. A., Bindels, R. J. M., Hoenderop, J. G. J., & Rigalli, J. P. (2021) · The FASEB Journal · doi:10.1096/fj.202002559r · Cited by 17
Gardani, C. F. F., Diz, F. M., Dondé, L. B., Rockenbach, L., Laufer, S., & Morrone, F. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1455469 · Cited by 17
“Increased levels of CD39 expression have been observed in various solid tumors (23), and extracellular vesicles derived from these cell types also contain CD39 and CD73 are believed to generate adenosine (58).”
BackgroundThe Role of Exosomal Epigenetic Modifiers in Cell Communication and Fertility of Dairy Cows
Abeysinghe, P., Turner, N. P., Garcia, I. M., Mosaad, E. M. O., Peiris, H. N., & Mitchell, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239106 · Cited by 16
Muñóz-Godínez, R., Mora‐García, M. D. L., Weiss‐Steider, B., Montesinos, J. J., Aguilar‐Lemarroy, A., García‐Rocha, R., Hernández‐Montes, J., Don‐López, C. A., Ávila-Ibarra, L. R., Torres‐Pineda, D. B., et al. (2020) · Mediators of Inflammation · doi:10.1155/2020/1678780 · Cited by 16
“In addition, extracellular vesicles derived from squamous cell carcinoma of the head and neck [16], prostate cancer [17], neuroblastoma [18], and other types of neoplastic cells [19, 20] can generate an immunosuppressive environment through the generation of Ado from ATP hydrolysis.”
BackgroundCancer exosomes in urine: a promising biomarker source
Panfoli, I. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.10.17 · Cited by 16
Dabaliz, A., Mahmoud, H. S., AlMutawa, R., & Mohammad, K. S. (2025) · Biomedicines · doi:10.3390/biomedicines13071640 · Cited by 16
“Different cancer types significantly express CD73 in TDEVs [216].”
Rodríguez-Pampín, I., González-Pico, L., Selas, A., Andújar-Arias, A., Prieto‐Díaz, R., & Sotelo, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100092 · Cited by 16
Wei, Q., Zhang, Y., Sun, L., Jia, X., Huai, W., Yu, C., Wan, Z., & Han, L. (2013) · Purinergic Signalling · doi:10.1007/s11302-013-9369-0 · Cited by 15
Metabolites: deciphering the molecular language between DCs and their environment
Minarrieta, L., Ghorbani, P., Sparwasser, T. D., & Berod, L. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0609-6 · Cited by 17
“ronment displays high concentrations of adenosine [117, 118], which promotes secretion of VEGF by DCs and inhibits their”
BackgroundA2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model
Huang, J., Zhang, D., Bai, Y., Yang, P. B., Xing, L., & Yu, J. (2020) · Journal of Cancer · doi:10.7150/jca.43966 · Cited by 15
“The adenosine 2A receptor (A2AR) pathway is the main pathway through which adenosine produces immunosuppressive effect [9, 10].”
BackgroundExosome: From leukemia progression to a novel therapeutic approach in leukemia treatment
Gholipour, E., Sarvarian, P., Samadi, P., Talebi, M., Movassaghpour, A. A., Motavalli, R., Hojjat‐Farsangi, M., & Yousefi, M. (2020) · BioFactors · doi:10.1002/biof.1669 · Cited by 15
Ectonucleotidase Modulation of Lymphocyte Function in Gut and Liver
Savio, L. E. B., Robson, S. C., & Longhi, M. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621760 · Cited by 17
“In experimental colitis induced by adoptive transfer of CD45RBhigh cells, administration of Cd39−/− Tregs resulted in less-effective control of the disease, when compared with WT Tregs (Gibson et al., 2015).”
BackgroundInfluentialShenoy, G. N., Bhatta, M., & Bankert, R. B. (2021) · Cells · doi:10.3390/cells10113155 · Cited by 15
Characteristics and mechanisms of T‐cell senescence: A potential target for cancer immunotherapy
Wu, H., Li, J., Zhang, Z., & Zhang, Y. (2024) · European Journal of Immunology · doi:10.1002/eji.202451093 · Cited by 14
The biology and function of extracellular vesicles in nasopharyngeal carcinoma (Review)
You, B., Shan, Y., Bao, L., Chen, J., Yang, L., Zhang, Q., Zhang, W., Zhang, Z., Zhang, J., Shi, S., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4202 · Cited by 14
“Clayton et al (46) reported that EVs secreted by tumor cells might contribute to the production of extracellular adenosine and modulate T cells in the tumor environment.”
Kellner, M., von Neubeck, B., Czogalla, B., Feederle, R., Vick, B., Jeremias, I., & Zeidler, R. (2022) · Biomedicines · doi:10.3390/biomedicines10040825 · Cited by 14
“Tumor-derived extracellular vesicles (TEVs) from CD73-positive cancer cells have been described to carry functional CD73 and suppress T-cell function through adenosine production [19].”
BackgroundTumor-Derived Exosomes Regulate Apoptosis of CD45+EpCAM+ Cells in Lung Cancer
Lu, S., Sun, Z., Liu, L., Li, P., Li, B., Li, W., Wu, Z., Zhao, M., Liu, W., Wang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903882 · Cited by 15
“Several investigations indicate that exosomes from tumor cells possess dissimilar immunosuppressive effects, including the inhibition of effector T cell activity (24), differentiation of fibroblasts to a myofibroblastic phenotype (25), and the functional enhancement of regulatory T cells.”
BackgroundTraberg, W. C., Uribe, J., Druet, V., Hama, A., Moysidou, C., Huerta, M., McCoy, R. S. A., Hayward, D., Savva, A., Genovese, A. M. R., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301194 · Cited by 14
Prendergast, G. C., & Metz, R. A. (2012) · OncoImmunology · doi:10.4161/onci.21358 · Cited by 15
Müller, G. A., Ussar, S., Tschöp, M. H., & Müller, T. D. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111307 · Cited by 14
“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“
Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 13
“Adenosine accumulates in the TME and binds to adenosine receptors on the surface of T cells (e.g., A2A and A2B receptors), activating the downstream cAMP-PKA signaling pathway (102, 103).”
Devvanshi, H., Kachhwaha, R., Manhswita, A., Bhatnagar, S., & Kshetrapal, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895254 · Cited by 13
Plasma extracellular vesicle surface-located GAS6/PROS1 and CD39/CD73 attenuate inflammation
Fabiano, M. P., Adamczyk, A. M., Gololobova, O. A., Mazzitelli, I. G., Leicaj, M. L., Grosso, T. M., Pérez, P. S., Alvarez, C. L., Schachter, J., Palmer, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116096 · Cited by 14
The Role of Tumor-Derived Vesicles in the Regulation of Antitumor Immunity
Ukrainskaya, V. M., Rubtsov, Y. P., Knorre, V. D., Maschan, M. A., Gabibov, A. G., & Stepanov, A. V. (2019) · Acta Naturae · doi:10.32607/20758251-2019-11-4-33-41 · Cited by 14
Composition, Physicochemical and Biological Properties of Exosomes Secreted From Cancer Cells
Ferguson, S. W., Megna, J. S., & Nguyen, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812774-2.00003-1 · Cited by 12
Methylation of the NT5E Gene Is Associated with Poor Prognostic Factors in Breast Cancer
Jeong, Y. J., Oh, H. K., Choi, H. R., & Park, S. H. (2020) · Diagnostics · doi:10.3390/diagnostics10110939 · Cited by 12
“Adenosine generated by CD73 exerts its biological function via the adenosinergic A2a receptor [7] and suppresses the function of T-lymphocytes [23].”
BackgroundViktorsson, K., Hååg, P., Shah, C., Franzén, B., Arapi, V., Holmsten, K., Sandström, P., Lewensohn, R., & Ullén, A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13288 · Cited by 12
Rocconi, R. P., Stanbery, L., Tang, M., da Silva, L. M., Walter, A., Monk, B. J., Herzog, T. J., Coleman, R. L., Manning, L., Wallraven, G., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00163-y · Cited by 12
Maralbashi, S., Aslan, C., Kahroba, H., Asadi, M., Soltani‐Zangbar, M. S., Haghnavaz, N., Jadidi, F., Salari, F., & Kazemi, T. (2024) · BMC Nutrition · doi:10.1186/s40795-024-00844-y · Cited by 12
“Clayton et al. reported the first study of the immunosuppressive role of exosomes by expressing CD39 (also known as ectonu-cleoside triphosphatediphosphohydrolase-1) and CD73 (also known as ecto-5 ʹ -nucleotidase) [33].”
BackgroundInfectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles
Sullivan, J. A., Al‐Adra, D. P., Olson, B. M., McNeel, D. G., & Burlingham, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01867 · Cited by 13
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
Wang, G., Liu, Y., Liu, S., Lin, Y., & Hu, C. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012647 · Cited by 12
Extracellular Vesicles in Cancer Progression: Are They Part of The Problem or Part of The Solution?
Scholl, J. N., Dias, C. K., Müller, L., Battastini, A. M. O., & Figueiró, F. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0256 · Cited by 12
Müller, G. A., Lechner, A., Tschöp, M. H., & Müller, T. D. (2021) · Biomedicines · doi:10.3390/biomedicines9030277 · Cited by 11
Novel classes of immunotherapy for breast cancer
Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 12
Li, X., Xu, R., Wei, X., Hu, H., Zhao, S., & Liu, Y. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02398 · Cited by 11
Immune interactions and regulation with CD39+ extracellular vesicles from platelet concentrates
Delorme, A. S., Laguide, A., Tamagne, M., Pinheiro, M. K., Cagnet, L., Neyrinck-Leglantier, D., Khelfa, M., Cléophax, S., Pirenne, F., & Vingert, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397967 · Cited by 10
The anti-metastatic micro-environment of the bone: Importance of osteocyte Cx43 hemichannels
Bultynck, G. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.003 · Cited by 11
The potential role of adenosine signaling in the pathogenesis of melanoma
Bahreyni, A., Rezaei, M., Khazaei, M., Fuiji, H., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.018 · Cited by 10
Huang, Y.-A., Chen, J., Wu, C., Hsu, C., Ko, A. M., Chen, L., & Kuo, M. (2021) · Biomedicines · doi:10.3390/biomedicines9060656 · Cited by 10
“ATP was reported to promote inflammation and inhibit the generation of regulatory T cells (Tregs) [33].”
BackgroundInfluentialSuppression of pro-inflammatory T-cell responses by human mesothelial cells
Lin, C., Kift-Morgan, A. P., Moser, B., Topley, N., & Eberl, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs612 · Cited by 10
“Exosomes play a potent role in driving cell–cell communication including suppression of T-cell responses via surface expressed CD39, CD73 and TGF-β [28–30].”
BackgroundDisagreements in the therapeutic use of mesenchymal stem cell-derived secretome
Sípos, F., & Műzes, G. (2022) · World Journal of Stem Cells · doi:10.4252/wjsc.v14.i6.365 · Cited by 10
Nie, L., Ma, J., Yu, Y., Tao, Y., Song, Z., & Li, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116699 · Cited by 11
Metadata
- Authors
- Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z.
- Affiliations
- Velindre Cancer Centre (GB)
- Department of Pharmacology, Radiology and Oncology, School of Medicine, Cardiff University, Velindre Cancer Centre , Whitchurch, Cardiff CF14 2TL ,
- Corresponding author
- Clayton, Aled
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 676-683
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153092839
- Cited by
- 540
- References
- 49
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 31 · 2023: 38 · 2022: 53 · 2021: 50 · 2020: 61 · 2019: 37 · 2018: 36 · 2017: 29 · 2016: 30 · 2015: 24 · 2014: 33 · 2013: 26 · 2012: 40
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- tumor-derived exosomes, CD39, CD73, extracellular adenosine, ATP hydrolysis, 5'-AMP, adenosine A2A receptor, cAMP signaling, T cell activation inhibition, tumor immunosuppression, mesothelioma, extracellular vesicles
- MeSH terms
- Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Apyrase, Humans, Hydrolysis, Mesothelioma, Phosphorylation, Pleural Neoplasms, Down-Regulation, Antigens, CD, 5'-Nucleotidase, Caco-2 Cells, Jurkat Cells, Cell Line, Tumor, T-Lymphocytes, Regulatory, Exosomes, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.